TMCnet News
Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting- SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharmacodynamic effects observed at the 3 mg/kg dose – AUSTIN, TX and DURHAM, NC, May 25, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the presentation of complete dose-escalation data from the Phase 1A monotherapy clinical trial of SL-172154 in PROC. These data will be featured in a poster presentation at the ASCO Annual Meeting, being held both virtually and in Chicago, IL from June 2-6, 2023. “We are excited to present data at ASCO that we believe positions SL-172154 as a differentiated CD47 inhibitor and further underscores its therapeutic potential in heavily pretreated PROC patients,” said Dr. Lini Pandite, MBChB, M.B.A., Chief Medical Officer of Shattuck. “We believe SL-172154, a dual CD47 inhibitor and CD40 agonist, has a differentiated safety and pharmacodynamic profile and its hexameric structure enables CD40 activation in a fundamentally different manner than prior CD40 agonist therapies studied in humans. Preliminary analysis of pre- and on-treatment tumor biopsies further validates its mechanism of action.” Dr. Pandite continued, “In the Phase 1A dose-escalation trial, SL-172154 had maximal CD47 and CD40 target engagement and CD40-dependent pharmacodynamic effects observed at the 3 mg/kg dose. SL-172154 had a favorable safety and tolerability profile across doses. Based on these encouraging data, we believe we have selected the optimal dose with maximal pharmacodynamic activity, which further supports our SL-172154 dose-expansion strategy in combination trials for patients with PROC. Our ongoing clinical trial of SL-172154 in combination with liposomal doxorubicin remains on track, and we expect to share initial data midyear. Additionally, we expect to share initial data from our clinical trial of SL-172154 in combination with mirvetuximab soravtansine in the second half of 2023.” The full abstract (#5544) is accessible on the ASCO Congress portal, and additional details are provided below.
Key Takeaways:
About the Phase 1A Dose Escalation Clinical Trial About SL-172154 About Shattuck Labs, Inc. Forward-Looking Statements Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, therapeutic potential, efficacy and clinical benefits of SL-172154, the safety, pharmacodynamic and tolerability profile of SL-172154, the optimal dosing of SL-172154, SL-172154 as a potentially differentiated CD47 inhibitor, the anticipated timing of the results from our clinical trials, and potential clinical benefit of our product candidates. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While we believe these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in our filings with the U.S. Securities and Exchange Commission (the “SEC”)), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include: global macroeconomic conditions and related volatility, expectations regarding the initiation, progress, and expected results of our preclinical studies, clinical trials and research and development programs; expectations regarding the timing, completion and outcome of our clinical trials; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; liquidity and capital resources; and other risks and uncertainties identified in our Annual Report on Form 10-K for the year ended December 31, 2022, and subsequent disclosure documents filed with the SEC. We claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law. The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD. Investor & Media Contact: 
|
